Skip to main content

Table 3 Reported outcomes for patients presenting with solitary plasmacytoma

From: Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel

Author

 

N

Local recurrence, %

Overall survival, % (years)

Progression-free survival, % (years)

Nahi et al. [4]

Total

191

NR

53% (8 years)

75% (2 years)

SBP

124

NR

56% (8 years)

65% (2 years)

EMP

67

NR

51% (8 years)

94% (2 years)

De Waal et al. [36]

Total

100

0%

68% (10 years)

50% (15 years)

SBP

66

0%

64%(10 years)

30% (15 years)

EMP

34

0%

77% (10 years)

88% (15 years)

Katodritou et al. [61]

Total

97

NR

78% (10 years)

59% (10 years)

SBP

65

NR

69% (10 years)

40% (10 years)

EMP

32

NR

86% (10 years)

50% (10 years)

Reed et al. [48]

Total

84

8%

78% (5 years)

47% (5 years)

SBP

59

3%

76% (5 years)

56% (5 years)

EMP

25

20%

85% (5 years)

30% (5 years)

Kilciksiz et al. [45]

Total

80

6%

73% (10 years)

NR

SBP

57

6%

68% (10 years)

NR

EMP

23

5%

89% (10 years)

NR

Ozsahin et al. [5]

Total

258

14%

55% (10 years)

35% (10 years)

SBP

206

14%

52% (10 years)

28% (10 years)

EMP

52

14%

72%(10 years)

74% (10 years)

Tsang et al. [47]

Total

46

17%

65% (8 years)

50% (8 years)

SBP

32

22%

NR

36% (8 years)

EMP

14

7%

NR

84% (8 years)

Liebross et al. [24]

SBP

57

4%

50% (10 years)

47% (10 years)

Liebross et al. [3]

EMP

22

7%

50% (10 years)

68% (10 years)

  1. NR not reported, SBP solitary bone plasmacytoma, EMP extramedullary plasmacytoma